Dirk Bühler

Maiwald - Germany

Partner

Elisenhof, Elisenstrasse 3
Munich
80335

+49897472660

Patent star 2022

German
English


Jurisdictions:

Germany

Practice areas:

Patent litigation
Patent prosecution
Patent strategy & counseling

Industry sectors:

Agriculture
Biotechnology
Food & beverage
Pharmaceutical
Utilities


Dirk Bühler specializes in the management of product-related patent portfolios worldwide as well as the associated opposition, nullity and infringement proceedings in the fields of pharmaceuticals, biotechnology and personalized therapy and diagnostics. He regularly advises clients on complex SPC matters and freedom-to-operate strategies in these areas.

His extensive experience enables him to bring strategic IP consultancy and patent portfolio creation/management into alignment with the economic interests of his clients in a rapidly changing market environment. Clients value his interdisciplinary approach of combining questions relating to patent law with regulatory requirements for marketing authorization of medicinal products in order to achieve the fullest protection possible.

Dirk has received numerous awards for his professional activities as patent attorney and regularly publishes articles on various aspects of patent law.

Year Joined Firm: 2001

Education/Alumni:

  • 2004 Admitted to practice as European patent attorney
  • 2004 Admitted to practice as German patent attorney
  • 2001 - 2004 Studied law for patent attorneys at the University of Hagen
  • 1998 - 2001 Doctoral degree in the field of biochemistry from the Freie Universität Berlin (doctoral research at the Max Planck Institute for Biochemistry)
  • 1992 - 1998 Studied biochemistry at the Freie Universität Berlin, the University of California, Berkeley and Heidelberg University

Network Memberships:

  • German Patent Attorney Association
  • epi
  • GBM
  • GRUR

  • Representation in opposition appeal proceedings leading to the BGH X ZB 8/12 „Dipeptidyl-Peptidase-Inhibitors“ decision
  • Representation in SPC application proceedings before the ECJ in case C-650/17 (Royalty Pharma/Sitagliptin)
  • Representation in infringement proceedings concerning non-invasive prenatal diagnostics (EP 0 994 963)
  • Attending to patent portfolios, opposition and appeal proceedings before the European Patent Office as well as participation in various infringement proceedings, inter alia concerning Oxygesic®, Tramundin®, and Targin®